Dr Reddy’s launches first generic version of Pataday eye drops in US

Pharma major Dr Reddy’s Laboratories Ltd said on Wednesday, 2025, that it has launched an over-the-counter generic version of the Pataday Extra Strength eye drop in the US, becoming the first company to market a generic version of the product.

It will be sold as olopatadine hydrochloride ophthalmic solution USP 0.7% as approved by the US Food and Drug Administration (FDA). The eye drop provides temporary relief from itchy eyes caused by allergens such as pollen and animal dander, the company said.

Dr Reddy’s said the launch expands its existing US OTC eye-care portfolio, which already includes lower-strength versions of olopatadine at 0.1% and 0.2%.

“The first-to-market launch is a testament to our deep capabilities in bringing store-brand equivalents of OTC brands in the US market. We are excited to deepen our collaboration with our retail customers through this important addition to our store-brand portfolio,” Milan Kalawadia, CEO of North America Generics at Dr Reddy’s, said in a statement.

In a regulatory filing, the company said its Pataday brand of eye drops recorded US sales of about $69.9 million in 2025.

Shares of the company ended 0.02% higher at ₹1,191.50 apiece today, January 14.

Also Read: Infosys headcount hits 11-quarter high with 5,043 additions in Q3